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S Frost1,2,3, Y Kanagasingam1,2, H Sohrabi4, J Vignarajan1,2, P Bourgeat1,5, O Salvado1,5, V Villemagne5,6,7, CC Rowe6,
S Lance Macaulay8, C Szoeke8,9, KA Ellis7,9,10, D Ames9,10, CL Masters7, S Rainey-Smith4, RN Martins4 and the AIBL Research
Group11
The earliest detectable change in Alzheimer’s disease (AD) is the buildup of amyloid plaque in the brain. Early detection of AD,
prior to irreversible neurological damage, is important for the efficacy of current interventions as well as for the development of
new treatments. Although PiB-PET imaging and CSF amyloid are the gold standards for early AD diagnosis, there are practical
limitations for population screening. AD-related pathology occurs primarily in the brain, but some of the hallmarks of the disease
have also been shown to occur in other tissues, including the retina, which is more accessible for imaging. Retinal vascular
changes and degeneration have previously been reported in AD using optical coherence tomography and laser Doppler
techniques. This report presents results from analysis of retinal photographs from AD and healthy control participants from the
Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing. This is the first study to investigate retinal blood
vessel changes with respect to amyloid plaque burden in the brain. We demonstrate relationships between retinal vascular
parameters, neocortical brain amyloid plaque burden and AD. A number of RVPs were found to be different in AD. Two of these
RVPs, venular branching asymmetry factor and arteriolar length-to-diameter ratio, were also higher in healthy individuals with
high plaque burden (P¼ 0.01 and P¼ 0.02 respectively, after false discovery rate adjustment). Retinal photographic analysis
shows potential as an adjunct for early detection of AD or monitoring of AD-progression or response to treatments.
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Introduction
The primary neuropathological hallmark of Alzheimer’s Dis-
ease (AD) is the presence of cerebral amyloid deposits
(plaques). The disease leads to cerebral (cortical and
particularly hippocampal) atrophy and is identified clinically
by a progressive decline in memory, learning and executive
function. In addition, the disease imposes a huge social and
economic burden on society.
Although post-mortem examination of the brain is required
for confirmation of AD, a diagnosis of ‘probable AD’ can be
made in patients, fulfilling the criteria set down by the National
Institute of Neurological and Communicative Disorders and
Stroke/Alzheimer’s Disease and Related Disorders Associa-
tion AD.1 Currently, a diagnosis of probable AD is only
possible when the condition has progressed, and consider-
able neurological damage has already occurred. The increas-
ing prevalence of AD in the population, along with the need to
treat the disease before the brain is irreversibly damaged,
calls for a sensitive and specific screening technology to
identify high-risk individuals before cognitive symptoms arise.
Although current treatments are limited in their efficacy, earlier
detection of AD would assist the development of interventions
aimed at preventing or delaying the neurodegenerative
process, and could contribute to development and evaluation
of new treatments.
Candidates for AD diagnostic or prognostic biomarkers are
being sought from many fields including genetics, blood
biomarkers, cerebrospinal fluid (CSF) proteomics and neu-
roimaging.2–11 One major genetic risk factor for sporadic AD
has been known for some time, the Apolipoprotein E e4 allele
(APOE E4).5 Two biomarkers are showing particular promise,
firstly, CSF concentrations of b amyloid (Ab), total t and
phosphorylated t peptides,6,7,11,12 and secondly, brain Ab
plaques imaged using Positron Emission Tomography (PET)
with C-11 PiB or F18 ligands.7,9–11 However, although these
are valuable diagnostic and secondary screening biomarkers,
they are not suited to population screening.
Cortical amyloid plaque burden can be evaluated in vivo
using PET neuroimaging with injected ligands such as
Pittsburgh compound-B (PiB), which selectively bind to Ab
plaques.7,9–11 PET-PiB imaging studies have revealed that
not only do AD-diagnosed individuals exhibit high PiB
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retention, but also B30% of cognitively normal elderly
individuals.7–9 High PiB retention is associated with progres-
sion to symptomatic AD,10 hence evidence is building that
PET-PiB imaging provides a test to identify preclinical
AD.9,13,14 Indeed research suggests that plaque burden can
be detected B15 years before cognitive symptoms arise.9
PET imaging has become highly useful for AD research
purposes, but due to the expense of the procedure and the
limited availability of PET facilities, it is not likely to become a
suitable primary screening technology for AD.
The absence of a suitable screening technology for AD has
motivated some researchers to look for biomarkers that might
exist elsewhere in the body, including the eye (see review15).
The retina is a developmental outgrowth of the brain and is
often referred to as nature’s brain slice as its laminar structure
of neural tissue can easily be imaged in vivo. Alzheimer’s
pathology in the retina could be a potential screening
measure, particularly since visual disturbance has often been
detected as an early complaint of AD patients.16,17 In addition,
many studies have reported reduced visual performance in
AD.17–33 However, as none of these visual deficiencies are
specific to AD, a newer field of research is investigating the
hypothesis that there might be specific pathological changes
in the eye that accompany the disease. There is hope that the
eye might yet yield biomarkers that are either highly specific
for AD, or can contribute to an AD-specific risk-profile
analysis, in combination with genetic, blood and/or other tests.
Retinal morphology reported in AD involves changes to the
vasculature34 and optic disc (optic nerve head),35–38 retinal
cell loss31,39–43 and thinning of the retinal nerve fiber
layer.34,44–46 The only study reporting retinal vascular
changes in AD was a small participant study by Berisha
et al.34 finding that AD participants had narrower blood column
diameter in the major superior temporal retinal venule and
decreased blood flow in this venule. These findings were
made with the use of a laser Doppler device; no study to date
has verified retinal vascular changes in AD using retinal
photography, which is more widely available. Detection of
retinal vascular changes in AD using retinal photography
could lead to a more practically applicable AD screening test.
Advances in digital retinal imaging have facilitated accurate
and reliable measurements of the optimality of the retinal
vasculature. This includes vascular attenuation, branching
geometry and measures of how effectively the vascular
network fills the retinal space. The present study investigated
whether vascular analysis of retinal photographs could
identify any retinal vascular parameters (RVPs) that may be
altered in AD. An additional question that was addressed by
this study was whether retinal changes occur late in the
disease process when AD is clinically diagnosed or earlier in
the disease process and therefore have prognostic potential
before conventional diagnosis is possible.
Methods
Participants. Participants for the retina study were recruited
from the Australian Imaging, Biomarkers and Lifestyle (AIBL)
study of ageing. A full description of the AIBL cohort is
reported elsewhere.47 AIBL participants were excluded from
the retinal screening study if they had history or evidence of
glaucoma, significant cataract or cataract surgery within the
prior 6 months. All retina study participants were white
Caucasians.
The AD participants fulfilled the National Institute of
Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria for probable AD.1 To address possible undiagnosed
hypertension in this study, the definition of hypertension was
extended to include both physician-diagnosed and identified
by elevated blood pressure (systolic pressure4140 mm Hg or
diastolic pressure 490 mm Hg) on the day of retinal imaging.
Neuroimaging methodology is reported elsewhere.48
Briefly, participants were neuroimaged for the presence of
fibrillar brain amyloid using PET-PiB.49,50 A bimodal distribu-
tion of PET-PiB Standardized Uptake Value Ratio (SUVR)
was observed in the healthy control (HC) group of the AIBL
study.51 Consequently, hierarchical cluster analysis yielded a
cutoff for neocortical SUVR of 1.5, separating high from low
plaque burden.51 Subjects were classified as PiB negative
(HC ) if their neocortex SUVR was o1.5, and PiB positive
(HCþ ) if their neocortex SUVR was 41.5.
All participants or legal guardians provided their written
informed consent, and all retinal imaging experiments were
approved by the Ethics Committee of the University of
Western Australia, according to the Helsinki Declaration.
The Ethics approval for the parent AIBL study was obtained
from the Austin Health Human Research Ethics Committee
and the Hollywood Private Hospital Ethics Committee.
In total, 148 participants entered the retinal vascular
parameter study (123 healthy control and 25 AD). The study
had two components: (i) a ‘clinical status study’ investigating
RVP differences between the 25 AD and 123 HC participants,
and (ii) a ‘neuroimaging study’ investigating RVP with respect
to neocortical plaque burden in HC participants with AIBL
neuroimaging data available (n¼ 45).
Retinal photography and grading. Digital retinal color
photographs (disc centered, 451 field) were collected with a
Canon CR-1 non-mydriatic camera (Canon USA, Lake
Success, NY, USA) in a darkened room. Retinal photographs
were analyzed with Singapore I Vessel Assessment (SIVA)
semiautomated software from the Singapore Eye Research
Institute. The analytical principles and reproducibility of
measurements using the SIVA software have been
described previously.52 Briefly, the RVPs were measured
from the width and branching geometry of the retinal vessels.
Nineteen RVPs were calculated for each retinal photograph
(see Table 1 for a description of RVPs).
The measured retinal zones of interest for the RVPs were
0.5–1.0 disc diameters away from the disc margin (zone B,
Figure 1) or 0.5–2.0 disc diameters away from the disc margin
(zone C, Figure 1). Measurement in these zones ensured that
the vessels had attained arteriolar status. The measured zone
for each parameter is listed in Table 1. Trained graders
followed a standardised protocol and performed corrections to
automated procedures as necessary.
Vascular calibers were calculated for the six largest
arterioles and six largest venules. Standard deviation of the
width in zone B (BSTD) was calculated for the arteriolar and
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venular networks. Summary measures of vascular equivalent
caliber were also calculated (central retinal arterial (CRAE)
and venular (CRVE) equivalent caliber), based on the
improved Knudston–Parr–Hubbard formula.53,54 CRAE and
CRVE represent the equivalent single-vessel parent caliber
(width) for the six arterioles and venules respectively. From
these indices, the arteriole-to-venule ratio (AVR) was calcu-
lated (AVR¼CRAE/CRVE).
Natural patterns such as vessel networks often exhibit
fractal properties, whereby they appear the same when
viewed over a range of magnifications. The fractal dimension
(FD) describes the range of scales over which this self-
similarity is observed. In this study, the fractal dimension of
the retinal vascular network was calculated using the box-
counting method.55 Larger values reflect a more complex
branching pattern.
Retinal vascular tortuosity is defined as the integral
of the curvature squared along the path of the vessel,
normalized by the total path length.56 All vessels in the
zone of interest with a width 440 mm were measured. The
estimates were summarized as the average tortuosity of
the measured vessels. A smaller tortuosity value indicates
straighter vessels.
The number of vessels with a first bifurcation (branch) in
zone C (Num1stB) was counted. Average metrics of these
branches were then calculated; branching coefficient (BC),
asymmetry factor (AF) and junctional exponent deviation (JE).
The branching coefficient at each vascular bifurcation is
defined as BC¼ (D12þD22)/(D02), where D1 and D2 are the
mean vessel widths of each daughter vessel and D0, the
mean width of the parent vessel. The AF is defined as AF¼
(D12)/(D22) (where D1XD2). JE expresses the deviation from
optimality of the ratio of vessel widths at a bifurcation.57 It is
defined as JE¼ (D03 (D13þD23))1/3/D0. In terms of mini-
mizing shear stress and work over a bifurcation, the optimum
values for BC and JE are BC¼ 21/3¼ 1.26 and JE¼ 0. All
vessels with their first bifurcation within the measured
zone were analyzed, with the average value for all vessels
reported.
LDR is defined as the vessel length from the midpoint of one
vascular bifurcation to the midpoint of the next bifurcation,
expressed as a ratio to the diameter of the parent vessel at the
first bifurcation.58 For all RVP names, a lowercase ‘a’ or ‘v’ at
the end of the name indicates a measurement of the arteriolar
or venular network respectively.
Statistical analysis. Demographic comparisons were per-
formed using a w2 test for categorical variables (gender,
hypertension, diabetes, smoking status and APOE E4 carrier
status), and analysis of variance (ANOVA) for the continuous
age variable (Po0.05 considered significant).
Across-group RVP scores were compared using analysis of
variance (ANCOVA), correcting for confounders (age, gen-
der, hypertension, diabetes, smoking status and APOE E4
carrier status). The likelihood of false positive results was
minimized by adjusting P-values according to the Benjamini
and Hochberg false discovery rate (FDR) method.59
Receiver-operating characteristic (ROC) curve analysis
was also performed to further illustrate the classification
accuracy of the RVPs. The area under the curve (AUC) of the
ROC curves was calculated; an AUC of 1 indicates perfect
classification ability into AD or HC, whereas an AUC near 0.5
indicates poor (random) classification ability. Logistical
models combining RVPs were created to assess combined
classification performance.
Table 1 Description of the 19 retinal vascular parameters (RVPs) measured for
each retinal photograph, along with the retinal zone of interest (see Figure 1) for
calculation of each parameter
Parameter Description Retinal
zone
CRAE Central retinal arteriolar equivalent caliber B
CRVE Central retinal venular equivalent caliber B
AVR Arteriole–venular Ratio (CRAE/CRVE) B
FDa Fractal dimension of arteriolar network C
FDv Fractal dimension of venular network C
BSTDa Zone B standard deviation Arteriole B
BSTDv Zone B standard deviation Venule B
TORTa Curvature tortuosity arteriole C
TORTv Curvature tortuosity venule C
Num1stBa Number of first branching arterioles C
Num1stBv Number of first branching venules C
BCa Branching coefficient arteriole C
BCv Branching coefficient venule C
AFa Asymmetry factor arteriole (or asymmetry
ratio)
C
AFv Asymmetry factor venule (or asymmetry
ratio)
C
JEa Junctional exponent deviation for arterioles C
JEv Junctional exponent deviation for venules C
LDRa Length diameter ratio arteriole C
LDRv Length diameter ratio venule C
Figure 1 Retinal zones utilized for retinal vascular analysis. Zone A is defined
as the region from 0 to 0.5 disc diameters away from the disc margin, zone B is
defined as the region from 0.5 to 1.0 disc diameters away from the disc margin and
zone C is defined as the region from 0.5 to 2.0 disc diameters away from the disc
margin. Retinal photograph from a healthy individual.
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All statistical analyses were conducted in XLstat 2011
(Microsoft Excel).
Results
Clinical status study. The clinical status cohort consisted
of 25 probable AD patients (age 72.4±7.5 years, 12 male
and 13 female individuals) and 123 healthy control partici-
pants (age 71.6±5.6 years, 55 male and 68 female
individuals). The demographics of this cohort are presented
in Table 2. Comorbid medical conditions considered relevant
to retinal vascular changes were hypertension and diabetes
mellitus. Participant-reported smoking (current or past history
of) was also considered due to previous reports linking
smoking with possible retinal vascular changes.60 HC and
AD groups did not differ significantly in age, gender,
hypertension, diabetes or smoking status. There was a
higher percentage of APOE E4 carriers in the AD group
(P¼ 0.019).
After FDR adjustment, significant differences in 13 of 19
RVPs were found between the AD and HC groups (Table 2
and Figure 2). Logistical models combining parameters were
created for combined AD classification. A logistic model
combining these 13 RVP’s provided good classification
performance (81.2% sensitivity, 75.7% specificity and 87.7%
AUC), compared with the logistic model including only age
and APOE E4 carrier status (68.0% sensitivity, 61.8%
specificity and 63.7% AUC).
Neuroimaging study. AIBL neuroimaging data was avail-
able for 45 HC participants. This neuroimaging cohort was
grouped according to high (SUVR41.5) or low (SUVRo1.5)
neocortical amyloid plaque burden (HCþ and HC
respectively). The demographics of the neuroimaging cohort
are presented in Table 3. There were 15 participants in the
HCþ group and 30 participants in the HC group. The
HCþ group had a higher percentage of APOE E4 carriers
than the HC group (P¼ 0.04); there were no significant
differences in the other demographic variables.
ANCOVA analysis revealed larger venular branching
asymmetry factor (AFv) and arteriolar length-to-diameter ratio
(LDRa) in the HCþ group (P¼ 0.01 and P¼ 0.02 respec-
tively, after FDR adjustment, see Figure 2D). These two
parameters were also larger in AD compared with HC, hence
these results are consistent with the hypothesis that RVP
changes may precede AD diagnosis.
Combined in a logistic model, AFv and LDRa could identify
high plaque burden in the HC group with 76.9% sensitivity,
69.2% specificity and 74.6% AUC. When combined with age
and APOE E4 carrier status, the classification performance
improved to 84.7% sensitivity, 69.2% specificity and 82.8%
AUC (compared with a logistic model with only age and APOE
E4 carrier status; 66.7% sensitivity, 73.3% specificity and
73.8% AUC).
Discussion
This study has demonstrated retinal vascular abnormalities in
AD, and has found an association between some retinal
abnormalities and neocortical amyloid plaque burden. The
results indicate that retinal photography might provide a
sensitive method (or adjunct to blood or other tests) for
detecting preclinical AD, allowing the possibility of population
screening.
Table 2 Demographics and descriptive RVP analysis for HC and AD groups, with ANCOVA and ROC analysis
Healthy control Alzheimer’s disease P-value FDR adj. P ROC: AUC% (s.d.%)
Number of participants (N) 123 25
Age: years (mean (s.d.)) 71.6 (5.6) 72.4 (7.5) 0.557a
Gender; Males: (N (%)) 55 (45) 12 (48) 0.764b
Hypertension: (N (%)) 44 (36) 11 (44) 0.439b
Diabetes: (N(%)) 6 (5) 2 (8) 0.533b
History of Smoking: (N(%)) 5 (4) 2 (8) 0.407b
APOE E4 Carrier: (N (%)) 38 (31) 14 (56) 0.019b
CRVE (mean (s.d.)) 182.7 (15.8) 169.7 (15.3) 0.000256c 0.0049d 0.703 (0.067)
FDv (mean (s.d.)) 1.210 (0.05) 1.171 (0.048) 0.000350c 0.0033d 0.716 (0.074)
BSTDa (mean (s.d.)) 4.101 (0.504) 4.538 (0.984) 0.00135c 0.0086d 0.595 (0.070)
BSTDv (mean (s.d.)) 3.983 (0.575) 4.433 (1.333) 0.00188c 0.0089d 0.541 (0.081)
Num1stBv (mean (s.d.)) 3.618 (1.052) 2.960 (1.136) 0.00560c 0.021d 0.660 (0.121)
Num1stBa (mean (s.d.)) 3.675 (1.075) 3.040 (0.978) 0.00710c 0.022d 0.675 (0.142)
FDa (mean (s.d.)) 1.235 (0.052) 1.201 (0.061) 0.00799c 0.021d 0.644 (0.075)
CRAE (mean (s.d.) 129.1 (10.3) 122.9 (12.4) 0.0115c 0.027d 0.612 (0.082)
AFa (mean (s.d.)) 0.778 (0.086) 0.824 (0.081) 0.0176c 0.037d 0.578 (0.081)
BCv (mean (s.d.)) 1.253 (0.165) 1.347 (0.240) 0.0186c 0.035d 0.556 (0.084)
Tortv ( 10 5) (mean (s.d.)) 7.660 (1.554) 6.952 (2.601) 0.0244c 0.042d 0.706 (0.073)
AFv (mean (s.d.)) 0.701 (0.097) 0.748 (0.095) 0.0301c 0.047d 0.616 (0.074)
LDRa (mean (s.d.)) 17.05 (7.87) 21.72 (9.55) 0.0333c 0.049d 0.651 (0.068)
JEv (mean (s.d.))  0.110 (0.378) 0.272 (0.338) 0.0483c 0.066d 0.539 (0.074)
Only RVPs that were significantly different between groups (Po0.05) in ANCOVA analysis are shown. Significant results after FDR adjustment shown in bold type.
Classification accuracy of RVP parameters from ROC analysis, AUC (area under the curve): AUC¼ 0.5 implies random separation of groups, AUC¼1.0 implies
perfect separation.
Refer to Table 1 for a description of the retinal vascular parameters.APOE E4 carrier status refers to carrier/non-carrier of an Apolipoprotein E e4 allele.
aAnalysis of variance (ANOVA) for the continuous age demographic variable (Po0.05 considered significant). bw2 test for categorical demographic variables (gender,
hypertension, diabetes, smoking status andAPOE E4 carrier status) (Po0.05 considered significant). cP-value from ANCOVA analysis of differences between groups
(including confounders). dANCOVA P-values adjusted for false discovery rate (FDR) (Po0.05 considered significant).
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Many studies have reported retinal degeneration in AD,
particularly thinning of the retinal nerve fiber layer and loss of
ganglion cells. However, only one previous study has reported
retinal vascular abnormalities in AD, involving thinning of the
major superior temporal venule blood column diameter and
reduced blood flow in this vessel, using a laser Doppler
device.34 Retinal photography is a more widely available
technology for investigating the retina, with eye clinics
and many optometrists now utilizing the technique to
provide regular retinal health checks. In addition, advances
in digital retinal imaging have facilitated accurate and
reliable measurements of the optimality of the retinal
vasculature. To the authors’ knowledge, this is the first study
to report retinal vascular abnormalities in AD using retinal
photography.
The retinal vascular abnormalities found in AD in the
present study can be broadly summarized as: (1) vascular
attenuation (CRVE, CRAE and LDRa), (2) increasing stan-
dard deviation of vessel widths (BSTD), (3) reduced complex-
ity of the branching pattern (FD, Num1stB), (4) reduced
optimality of the branching geometry (AF, BCv) and (5) less
tortuous venules (Tortv). These findings add to the growing
evidence that retinal changes occur in AD. We demonstrate
for the first time that these changes can be detected using
noninvasive, readily available retinal photography. Models
combining RVPs perform well at distinguishing diagnosed AD
patients from healthy controls. However these models are
optimized for the present data set and should be tested on
other cohorts in future.
Figure 2 Boxplot comparison of (a) Central retinal venular equivalent caliber (CRVE), (b) Fractal dimension of the venular network (FDv) and (c) Asymmetry factor of the
venular network (AFv) across HC (n¼ 123) and AD (n¼ 25) groups. The HC group includes individuals with high plaque burden (HCþ ), low plaque burden (HC ) and
unknown plaque burden. AFv is also compared across HC (n¼ 30) and HCþ (n¼ 15) subgroups (d).
Table 3 Demographics of the neuroimaging subgroups
HC HCþ P-value
Number of participants: (N) 30 15
Age: years (mean (s.d.)) 70.4 (5.3) 73.7 (6.3) 0.08a
Gender; Males: (N (%)) 15 (50) 9 (60) 0.53b
n(hypertension) 11 (37) 6 (40) 0.52b
n(diabetes) 1 (3) 2 (13) 0.99b
n(smokers) 2 (7) 0 (0) 0.99b
APOE E4 carrier: (N (%)) 14 (47) 12 (75) 0.04b
HC : healthy controls with low plaque burden, HCþ : healthy controls with
high plaque burden. s.d.: standard deviation. No demographic was significantly
different between groups. Significant results in bold type.
aAnalysis of variance (ANOVA) for the continuous age demographic variable
(Po0.05 considered significant). bw2 test for categorical demographic variables
(gender, hypertension, diabetes, smoking status and APOE E4 carrier status)
(Po0.05 considered significant).
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An additional question addressed by the present study was
whether these changes occur late in the disease process
when AD is clinically diagnosed, or earlier in the disease
process, providing prognostic potential before conventional
diagnosis is possible. To address this question, RVPs were
compared between healthy individuals with high (HCþ ) and
low (HC ) neocortical plaque burden. High plaque burden is
predictive of progression to AD,9,13,14 so the HCþ group is
believed to represent those participants in the preclinical
stage of AD.
Two of the RVPs that were found to be elevated in AD,
venular branching AFv and LDRa, were also higher in the
HCþ group compared with the HC group. These results
indicate that changes to retinal vascular widths and branching
may be occurring early in AD pathogenesis, during the
asymptomatic plaque deposition stage before subsequent
cognitive decline. Hence, retinal photography combined with
vascular analysis indicates potential as an adjunct to detect
preclinical AD.
Our findings indicate a relationship between RVPs, neocor-
tical amyloid plaque load and AD. It is of interest to evaluate the
possible pathophysiological basis of these results. Although
cerebral amyloid plaques and neurodegeneration (particularly
hippocampal) are the main hallmarks of AD, cerebral vascular
changes are also known to occur in the disease. In particular,
vascular disease was also evident in the original and disease
defining cases of Alzheimer61 and cerebral amyloid angio-
pathy, characterized by deposition of amyloid in vessel walls,
has been well documented in AD.62–64 Given the homology
between the retinal and cerebral microvasculature,65 con-
comitant amyloid angiopathy in AD might extend to the retina,
with associated destruction of the vessel walls, resulting in
changes to vascular widths and topology.
As vascular changes and neurodegeneration appear to be
occurring in both the brain and retina in AD, there is some
suggestion that AD-specific pathology could also be occurring
in the retina. Fascinatingly, preliminary evidence is emerging
that Ab plaques may occur in the human AD retina,66 possibly
providing a more accessible location to assess AD-specific
neuropathology. However, further research is needed to
determine the nature of these retinal plaques and their
relationship with AD and possible concomitant ocular disease.
In addition, potential relationships between retinal degenera-
tion reported in AD,31,34–46 retinal Ab plaques and the retinal
vascular changes reported in the present study are intriguing,
but require further investigation.
Interestingly, a previous study examining RVPs in dementia
reported that wider retinal venules are associated with an
increased risk of vascular dementia.67 As AD and vascular
dementia are the most common forms of dementia, our
contrasting results demonstrating lower venular caliber in AD
encourage further research into retinal vascular changes that
show potential to discriminate between these forms of
dementia.
Hypertension is a significant risk factor for AD and causes
arteriolar narrowing and venular widening in the retinal
circulation.60 Some studies have reported that these vascular
changes may precede clinical hypertension,68,69 a possibility
that must be considered in this study. However, the opposing
results for CRVE in hypertension and AD suggest that this is
unlikely to be the cause of the observed results. Although, FD
has been found to be lower in nonproliferative diabetic
retinopathy of the macular region,70,71 all diabetic participants
in the present study were controlled and did not exhibit
diabetic retinopathy.
Measurements of ocular refractive error were not available
for this study. Dimensional parameters (CRAE, CRVE and
BSTD) were therefore subject to refractive error, unlike the
remaining RVPs which are dimensionless. Bias from magni-
fication differences is not profound in most eyes within the
refractive power range of ±3 diopter72 and refractive errors
are not likely to be associated with AD and hence are unlikely
to confound the associations assessed. The vessel width
reduction observed in AD, in contrast with the increase in the
standard deviation of vessel widths, lends support to vessel
width changes in AD that are independent of magnification
effects, as magnification effects alone would be expected to
influence both parameters in the same manner. It is possible
that vessel narrowing in AD affects vessels selectively, hence
increasing the standard deviation of vessel widths.
The major limitation of this study is the size of the AD and
neuroimaging cohorts. Future studies with larger cohorts are
needed to further examine associations between RVPs and
AD or neocortical plaque burden. The major strength of the
study are the well-characterized cohorts, including neuroima-
ging data that enable deeper interrogation of associations
between RVPs and AD.
The results of the present study indicate that retinal
photography combined with vascular analysis might provide
an adjunct for detecting preclinical AD, or for monitoring
disease progression and response to intervention. The study
also found retinal abnormalities in AD that oppose those
previously reported in vascular dementia, suggesting poten-
tial for retinal vascular analysis to distinguish between these
most common forms of dementia. Natural variation in RVPs
between individuals may limit the utility of a single retinal
photography screening test for AD, hence it is possible that
retinal monitoring, allowing longitudinal analysis of retinal
changes, might facilitate more accurate preclinical detection
or monitoring of AD. Future longitudinal studies are planned to
further explore this possibility and to determine the time
course of retinal changes in AD.
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